GlassScriptPhysician profile
Miyoshi Henry
NPI 1184829525
$11,704.97
in general payments reported to CMS, 2019-2025
49 companies · $1,540 in 2025
The $1,540 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,407 · 2020: $1,482 · 2021: $2,036 · 2022: $1,621 · 2023: $1,852 · 2024: $1,768 · 2025: $1,540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,159.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,786.76 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,341.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $932.25 | 2021-2025 | |
| Amgen INC. | $786.88 | 2019-2025 | Repatha, Prolia, Evenity |
| Astrazeneca Pharmaceuticals LP | $784.89 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $744.38 | 2019-2025 | |
| Lilly USA, LLC | $545.32 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Dexcom, INC. | $462.43 | 2020-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $443.03 | 2019-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $357.89 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $344.21 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $331.96 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $326.41 | 2019-2024 | Ofev, Jardiance |
| E.R. Squibb & Sons, L.L.C. | $271.06 | 2019-2024 | Eliquis |
| Ironwood Pharmaceuticals, INC | $268.58 | 2020-2024 | Linzess |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miyoshi Henry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.